Overview

Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Goserelin may interfere with the growth factor and may stop the tumor from growing. Bicalutamide may prevent androgens from stimulating the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of goserelin plus bicalutamide in treating patients who have refractory or recurrent cancer of the ovary, fallopian tube, or peritoneum.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bicalutamide
Goserelin
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed epithelial carcinoma arising in the
ovary, fallopian tube, or peritoneum, in second or greater remission Failed initial therapy
with persistent or recurrent disease Cytoreductive surgery AND At least 1 platinum-based
chemotherapy regimen No evidence of disease within 4 months of salvage chemotherapy CA-125
less than 35 U Negative physical exam No abdominal or pelvic disease by CT

PATIENT CHARACTERISTICS: Age: Adult Performance status: Karnofsky 60-100% Life expectancy:
Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at
least 100,000/mm3 Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT
less than 2 times ULN Alkaline phosphatase less than 2 times ULN Renal: Not specified
Other: No other active invasive malignancy No inability to receive subcutaneous injection
No inability to tolerate oral medication

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See
Disease Characteristics Other: No concurrent oral anticoagulants